** Shares of Mesoblast rise as much as 46% to A$2.890, their highest since Dec. 16, 2020
** Stock posts its biggest intraday percentage rise since April 2
** Drug developer says U.S. Food and Drug Administration approved co's cell therapy for graft-versus-host disease
** About 28.1 mln shares change hands, compared with the 30-day average volume of around 6.3 mln
** Stock up over 825% YTD, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。